‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
2007 · British Journal of Cancer · 92 citations
https://doi.org/10.1038/sj.bjc.6604068
A
Ar Kalikaki
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
0
Papers
0
Citations
Ar Kalikaki is an academic researcher.
Papers by this author
worksChat about Author
Papers
Chat
Click to start Chat